53 results
424B3
RGBP
Regen BioPharma Inc
24 Apr 24
Prospectus supplement
1:28pm
guidance related to the valuation allowance assessment when recognizing deferred tax assets resulting from unrealized losses on available-for-sale debt
424B3
RGBP
Regen BioPharma Inc
19 Jan 24
Prospectus supplement
1:29pm
to the valuation allowance assessment when recognizing deferred tax assets resulting from unrealized losses on available-for-sale debt securities. The new
424B3
RGBP
Regen BioPharma Inc
20 Nov 23
Prospectus supplement
9:38am
, with tumor assessment before therapy and at 6 and 12 months.
On May 12, 2021 the “Company executed a consulting agreement with Biotech Research Group … is anticipated to last one year, with tumor assessment before therapy and at 6 and 12 months.
DiffronC: NR2F6 is a transcription factor that is present
424B3
xbwdbsv8uie2ol2 li
2 Oct 23
Prospectus supplement
1:42pm
424B3
ylzpu3kvvsl
15 May 23
Prospectus supplement
10:25am
8-K
77ttgz
19 Oct 21
Entry into a Material Definitive Agreement
9:30am